Latest news with #SakarHealthcare
Mint
8 hours ago
- Business
- Mint
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 19 June 2025
Breakout stocks buy or sell: Indian stock markets ended in the red for the second consecutive session on Wednesday, June 18, amid rising geopolitical tensions between Israel and Iran, which dampened investor sentiment. The Sensex declined by 139 points, or 0.17 per cent, to close at 81,444.66, while the Nifty 50 dropped 41 points, or 0.17 per cent, to settle at 24,812.05. The BSE Midcap and Smallcap indices also slipped, each losing 0.34 per cent. Sumeet Bagadia, Executive Director at Choice Broking, believes that Indian stock market sentiment is cautious to positive as the Nifty 50 index is trading in 24,500 to 25,200 range. Speaking on the outlook of Indian stock market, Bagadia said, ' Bullish or bearish trend can be assumed on the breakage of either side of the range. So, one should maintain stock-specific approach and look at those stocks that are looking strong on the technical chart. Looking at breakout stocks can be a good option." Sumeet Bagadia recommends five shares to buy today — Sakar Healthcare, Yuken India, DEE Development Engineers, NDR Auto Components, and Pearl Global Industries. 1] Sakar Healthcare: Buy at ₹ 363, target ₹ 390, stop loss ₹ 350; 2] Yuken India: Buy at ₹ 1108, target ₹ 1190, stop loss ₹ 1080; 3] DEE Development Engineers: Buy at ₹ 300, target ₹ 322, stop loss ₹ 292; 4] NDR Auto Components: Buy at ₹ 988.2, target ₹ 1060, stop loss ₹ 950; 5] Pearl Global Industries: Buy at ₹ 1467.8, target ₹ 1580, stop loss ₹ 1414. Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
a day ago
- Business
- Business Standard
Sakar Healthcare surges after receiving marketing authorization in EU for its oncology product
Sakar Healthcare jumped 4.65% to Rs 344.20 after the company announced the receipt of second marketing authorization (MA) of oncology injection (product registration) for the European Union (EU). The companys dossier compiled under EU guidelines have fetched this second approval in continuation to the journey of their research-driven API-integrated EU GMP approved oncology formulation manufacturing unit. While the earlier product intends to treating breast cancer, non-small cell lung cancer and prostate cancer, this second one is for treating colorectal cancer; both are widely prevalent type of cancers. "Strategically the second MA now widens the door to export and commercialise injection products to the European countries, with the first MA that received approval in April-2025 is in process of its FIRST commercial supply, Sakar Healthcare stated. It further said that with another few products (mix of liquid, lyophilised injections and oral solids) presently under registration in the EU, the company expects the grant of these MAs one-by-one within next few months. These MAs will speed up the export of multiple oncology products to the EU region manufactured at Sakars state-of-the-art vertically integrated oncology product manufacturing site. Sakar Healthcare manufactures pharmaceutical formulations in the form of liquid injectables, tablets/ capsules, oral liquid syrups, dry powder injections and syrups. The company manufactures generic formulations in 24 therapeutic categories, such as antibiotics, cough preparations, vitamins and mineral supplements, among others. Also, the company entered the oncology drugs segment with units for oncology formulations, APIs and injectables. The company's consolidated net profit surged 84.62% to Rs 5.76 crore as revenues increased by 16.67% to Rs 50.24 crore in Q4 FY25 as compared with Q4 FY24.
Business Upturn
a day ago
- Business
- Business Upturn
Sakar Healthcare secures second EU marketing authorization for Oncology Injection
By Aman Shukla Published on June 18, 2025, 13:32 IST Sakar Healthcare has received its second Marketing Authorization (MA) for an oncology injection in the European Union, marking another milestone in its global expansion. This newly approved product is intended for the treatment of colorectal cancer, a highly prevalent condition across Europe. The approval was granted based on a dossier compiled under stringent EU regulatory guidelines, reinforcing the strength of Sakar's research-led, EU GMP-certified oncology formulation facility. The company's first oncology injection—approved in April 2025 for treating breast cancer, non-small cell lung cancer, and prostate cancer—is already progressing towards its first commercial supply. With this second MA, Sakar can now commercially export its oncology injection products across EU markets. Several other products, including liquid and lyophilised injections as well as oral solids, are currently under review. Approvals for these are expected in the coming months, further accelerating Sakar's presence in the European oncology segment. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Standard
15-05-2025
- Business
- Business Standard
Sakar Healthcare consolidated net profit rises 84.62% in the March 2025 quarter
Sales rise 16.67% to Rs 50.24 crore Net profit of Sakar Healthcare rose 84.62% to Rs 5.76 crore in the quarter ended March 2025 as against Rs 3.12 crore during the previous quarter ended March 2024. Sales rose 16.67% to Rs 50.24 crore in the quarter ended March 2025 as against Rs 43.06 crore during the previous quarter ended March 2024. For the full year,net profit rose 49.96% to Rs 17.50 crore in the year ended March 2025 as against Rs 11.67 crore during the previous year ended March 2024. Sales rose 15.80% to Rs 177.58 crore in the year ended March 2025 as against Rs 153.35 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 50.2443.06 17 177.58153.35 16 OPM % 31.3125.48 - 27.9825.01 - PBDT 11.719.66 21 42.4633.95 25 PBT 6.244.80 30 21.5815.90 36 NP 5.763.12 85 17.5011.67 50
